申请人:Heidebrecht Richard
公开号:US20090221669A1
公开(公告)日:2009-09-03
The present invention relates to a novel class of disubstituted aniline compounds. These compounds can inhibit hi-stone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the compounds of the instant invention and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of these compounds in vivo.
本发明涉及一类新型的二取代苯胺化合物。这些化合物可以抑制组蛋白去乙酰化酶,并适用于选择性诱导终末分化,阻止肿瘤细胞的生长和/或凋亡,从而抑制这些细胞的增殖。因此,本发明的化合物可用于治疗具有肿瘤细胞增殖特征的患者。本发明的化合物还可用于预防和治疗TRX介导的疾病,例如自身免疫、过敏和炎症性疾病,以及中枢神经系统(CNS)疾病的预防和/或治疗,例如神经退行性疾病。本发明还提供了包含本发明的化合物的制药组合物和这些制药组合物的安全用量方案,这些方案易于遵循,并在体内产生治疗有效量的这些化合物。